Αρχική World News Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses... World News Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma Από Ogkologos - 5 Οκτωβρίου, 2026 91 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the first-in-human phase I study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Treatment Strategy for ecDNA-Driven Tumors Shows Potential 5 Δεκεμβρίου, 2024 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... 22 Ιουνίου, 2026 Study Suggests Statins May Help Keep Breast Cancer from Spreading to... 24 Ιουνίου, 2020 FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab... 26 Αυγούστου, 2026 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... How My Navy Career Helped Shape My Positive Attitude During My... Blood test could tailor treatment after surgery Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room.